Leinco Technologies

Anti-Human Fractalkine

Product Code:
 
LEI-C1306
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C1306-20ug20 ug£221.00
Quantity:
LEI-C1306-0.1mg0.1 mg£574.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Long Description:
Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4
Target:
Fractalkine

References

1. Patel DD et al. (1998) J Exp Med. 188: 1413 2. Hwang ST et al. (1999) Eur J Immunol. 29: 2551 3. Muller GA et al. (2008) Z Rheumatol. 67: 424 4. Mori M et al. (2005) Int J Oncol. 26: 41